Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting by Mourah, Samia et al.
Detection of BRAF V600 Mutations in Melanoma:
Evaluation of Concordance between the Cobas 4800
BRAF V600 Mutation Test and the Methods Used in
French National Cancer Institute (INCa) Platforms in a
Real-Life Setting
Samia Mourah, Marc G. Denis, Fabienne Escande Narducci, Je´roˆme Solassol,
Jean-Louis Merlin, Jean-Christophe Sabourin, Jean-Yves Scoazec, L’Houcine
Ouafik, Jean-Franc¸ois Emile, Remy Heller, et al.
To cite this version:
Samia Mourah, Marc G. Denis, Fabienne Escande Narducci, Je´roˆme Solassol, Jean-Louis Mer-
lin, et al.. Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance
between the Cobas 4800 BRAF V600 Mutation Test and the Methods Used in French Na-
tional Cancer Institute (INCa) Platforms in a Real-Life Setting. PLoS ONE, Public Library of
Science, 2015, 10 (e0120232), <10.1371/journal.pone.0120232>. <hal-01217819>
HAL Id: hal-01217819
https://hal-amu.archives-ouvertes.fr/hal-01217819
Submitted on 21 Oct 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
RESEARCH ARTICLE
Detection of BRAF V600 Mutations in
Melanoma: Evaluation of Concordance
between the Cobas1 4800 BRAF V600
Mutation Test and the Methods Used in
French National Cancer Institute (INCa)
Platforms in a Real-Life Setting
Samia Mourah1,2*, Marc G. Denis3, Fabienne Escande Narducci4, Jérôme Solassol5, Jean-
Louis Merlin6, Jean-Christophe Sabourin7, Jean-Yves Scoazec8,9, L’Houcine Ouafik10,
Jean-François Emile11, Remy Heller12, Claude Souvignet13, Loïc Bergougnoux13, Jean-
Philippe Merlio14
1 Department of Pharmacology-Genetics, AP-HP, Saint-Louis Hospital, Paris, France, 2 INSERMUMRS
976 Paris, F-75010, France, 3 Department of Biochemistry, Nantes University Hospital, Nantes, France, 4
Department of Molecular Biology and Biochemistry, Lille Regional University Hospital, Lille, France, 5
Department of Biology—Pathology, Montpellier University Hospital, Montpellier, France, 6 Department of
Tumor Biology, Alexis Vautrin Center, Vandoeuvre les Nancy, France, 7 Department of Pathology—
Cytopathology, Rouen University Hospital, Rouen, France, 8 Laboratory of Pathology and Cytopathology,
Edouard Herriot Hospital, Lyon, France, 9 Department of Biology and Pathology, Gustave Roussy Hospital,
Villejuif, France, 10 Department of Cancer Biology, Marseille Nord University Hospital, Marseille, France, 11
Department of Pathology, Ambroise Paré Hospital, Boulogne-Billancourt, France, 12 Department of
Microbiology and Molecular Biology, Colmar hospital, Colmar, France, 13 Roche, Boulogne-Billancourt,
France, 14 Department of Tumor Biology, Bordeaux University Hospital, Bordeaux, France
* samia.mourah@sls.aphp.fr
Abstract
Vemurafenib is approved for the treatment of metastatic melanoma in patients with BRAF
V600 mutation. In pivotal clinical trials, BRAF testing has always been done with the ap-
proved cobas 4800 BRAF test. In routine practice, several methods are available and are
used according to the laboratories usual procedures. A national, multicenter, non-interven-
tional study was conducted with prospective and consecutive collection of tumor samples.
A parallel evaluation was performed in routine practice between the cobas 4800 BRAF
V600 mutation test and home brew methods (HBMs) of 12 national laboratories, labelled
and funded by the French National Cancer Institute (INCa). For 420 melanoma samples
tested, the cobas method versus HBM showed a high concordance (93.3%; kappa = 0.86)
in BRAF V600 genotyping with similar mutation rates (34.0% versus 35.7%, respectively).
Overall, 97.4% and 98.6% of samples gave valid results using the cobas and HBM, respec-
tively. Of the 185 samples strictly fulfilling the cobas guidelines, the concordance rate was
even higher (95.7%; kappa = 0.91; 95%CI [0.85; 0.97]). Out of the 420 samples tested, 28
(6.7%) showed discordance between HBM and cobas. This prospective study shows a high
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concordance rate between the cobas 4800 BRAF V600 test and home brew methods in the
routine detection of BRAF V600E mutations.
Introduction
The incidence and mortality rates of melanoma have risen sharply throughout the world over
the past few decades and the incidence of melanoma has shown the largest increase of all can-
cers [1]. Cutaneous melanoma is the most serious skin cancer due to its high potential for me-
tastasis[2,3] and, until recently, no effective treatments were available [4].
Recent discoveries in cell signaling pathways that control cellular proliferation have provid-
ed a greater understanding of the biology that underlies melanoma and have elucidated the
central role of BRAF kinase [5,6]. The mitogen-activated protein kinase (MAPK) pathway is a
key regulator of melanoma proliferation and is critical to oncogenic signalling in the majority
of patients with cutaneous melanoma. Activating BRAF V600 mutations have been shown to
occur in 40%–60% of malignant melanomas [7,8], including in recent reports based on analy-
ses of French patients [9,10].
The discovery of such somatic mutations in the BRAF gene has paved the way for develop-
ing targeted therapies in melanoma [11,12]. Indeed, the importance of targeting this pathway
for melanoma treatment using specific BRAF inhibitors has been successfully demonstrated in
BRAF V600-mutated melanoma in preclinical models [13,14] and, more importantly, in clini-
cal trials [15–18].
Vemurafenib (Zelboraf), a selective BRAF inhibitor, has been shown to increase the overall
median survival by 3.6 months (13.2 months in the vemurafenib arm versus 9.6 months in the
dacarbazine arm; HR, 0.37; 95%CI, 0.26 to 0.55) [15] and has recently been approved as a first
line therapy in BRAF (V600E in the USA, V600 in Europe) mutated advanced melanoma
[15,19].
Vemurafenib was granted Marketing Authorization (MA) in Europe in February 2012 for
the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic
melanoma. The approval of vemurafenib has made BRAF V600 molecular genotyping manda-
tory requiring molecular diagnostic testing in order to select patients who will benefit from this
therapy [15]. Therefore, vemurafenib was developed conjointly with the cobas 4800 BRAF
V600 Mutation Test (Roche Molecular Diagnostics) using allele-specific real-time polymerase
chain reaction (PCR) and TaqMelt technology to determine BRAF V600 mutation status in
DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue [20]. It was de-
signed to detect the predominant BRAF V600E mutation with high sensitivity (less than 5% of
V600E sequence in a wild-type sequencing environment).
In August 2011, the cobas 4800 BRAF V600 Mutation Test reagent obtained European
Community-In Vitro Diagnostic (EC-IVD) labeling for the detection of the main BRAF V600
somatic mutations in routine diagnostic testing. The analytical performances of the reagent
have been evaluated in several multicenter studies [21–23].
In France, the French National Cancer Institute (INCa) has set up a national network of 28
regional molecular cancer genetics platforms where selective molecular tests, including BRAF
V600 genotyping, are routinely performed using methods specific to each laboratory [24,25].
In this real-life study, we evaluated the concordance of the cobas 4800 BRAF V600 Mutation
Test relative to the home brew methods (HBM) used at 12 participating INCa platforms when
tested in parallel for BRAF genotyping in melanoma samples.
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Materials and Methods
Melanoma samples
This national, multicenter, prospective, non-interventional study included 420 consecutive
tumor samples of histologically proven melanoma tumor tissue, surgical specimens or biopsies
of primary tumors or metastases (regardless of disease stage), fixed and paraffin-embedded.
Tumor samples for which the fixative was unknown were excluded and no sample could be in-
cluded in the study more than once. At selection, 12 INCa platform laboratories equipped with
the cobas 4800 System and routinely performing BRAF V600mutation testing were invited to
participate to the study and eligible tumor samples were consecutively included. The study was
conducted in accordance with the recommendations of the professional code of ethics and
good epidemiological practices established by the Association of French-speaking Epidemiolo-
gists [26]. The solicited Ethics Committee (Comité de Protection des Personnes/CPP) consid-
ered that neither patient consent nor CPP approval was required for this non-interventional
study. Patients data was anonymized during the conduct of the research in an e-CRF. The
BRAF mutation testing was done first using the routine method and secondarily using cobas
4800 automated test for the purpose of the study. The samples dedicated to cobas test were
anonymized with a patient code. Data analysis performed by the investigator was completely
anonymized. The investigator was not the testing operator. Operators performed the test inde-
pendently of the investigator.
BRAF V600 Detection Methods
BRAFmutation testing was carried out in parallel by the cobas 4800 BRAF V600 Mutation Test
(Roche Molecular Diagnostics) and the HBMs routinely used by the 12 participating INCa mo-
lecular genetics platforms in French hospitals (Boulogne-Billancourt, Colmar, Lille, Lyon, Mar-
seille, Montpellier, Nantes, Paris, Pessac, Rouen, Vandoeuvre les Nancy and Villejuif). The
HBMs included direct Sanger sequencing, pyrosequencing [27], allele-specific PCR [10], SNaP-
shot and high-resolution melting (HRM) analysis followed by Sanger sequencing in cases with
abnormal curve [9]. DNA extraction was performed using either manual or automated
registered techniques.
BRAFmutation testing with the cobas 4800 BRAF V600 Mutation Test was performed by
personnel trained in the techniques of PCR and the use of the cobas 4800 System in each center
and following the procedures in the Package Insert and in the cobas 4800 System Operator's
Manual. The manufacturer’s protocol included another DNA extraction starting from the
same tumor sample (mainly FFPE sections), also according to the supplier’s recommendations.
The cobas 4800 BRAF V600 Mutation Test has been optimized and validated for formalin-
fixed paraffin embedded (FFPE) tissues. Other cobas criteria include formaldehyde fixation,
slice thickness5 μm, dewaxing, percentage of tumor cells50% and DNA concentration
5 ng/μL. However, as the study evaluated the concordance in routine practice, the cobas
method was also applied to other types of material with different fixatives (as shown in Fig. 1).
In case of discordance between the local HBM technique and the cobas method, the molecu-
lar biologist was responsible for making the decision to either make a cross-over between the
two samples of extracted DNA and to reanalyze them by the two different techniques or to per-
form another analysis (retesting, immunohistochemistry for BRAF V600E, etc) according to
his/her usual practices.
Concordance between BRAF V600 Detection Techniques
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Statistical Analysis
The primary study objective was to assess the concordance between the cobas 4800 BRAF
V600 mutation test and the HBMs for detection of BRAF V600 mutations in melanoma. The
primary endpoint was the discordance rate between the INCa molecular laboratory HBM and
the cobas 4800 BRAF V600 mutation test for detection of BRAF V600 mutations in melanoma.
Secondary endpoints were tumor sample characteristics, descriptions of preanalytical and ana-
lytical methods, and management of discordant cases. No changes in the analyses were imple-
mented after protocol signature. The scientific committee requested several additional
exploratory analyses, including description of DNA in quantitative amounts and qualitative
classes, and description of the preanalytical and analytical methods according to the BRAF
V600 testing results.
A total of 384 tumor samples would allow to detect a rate of 10% of discordance between
the two methods with a precision of 3% (α = 5%) for the 95% confidence interval (CI). The
total number of samples to be included in this study was 400, assuming a 5% rate of non-evalu-
able samples (damaged equipment, too few tumor cells, etc).
The principal analysis was carried out on the population of evaluable samples. Initially, total
mutation rates for the routine methods of INCa molecular genetics platform laboratories and
for the cobas 4800 BRAF V600 Mutation Test were described as "V600 mutation", "No V600
mutation" or "Invalid result" (defined as samples that were evaluable but the results could not
be interpreted). A discordance was defined when the result of the usual laboratory method was
different from that of the cobas 4800 BRAF V600 Mutation Test. The Kappa coefficient was
presented with its 95% CI to evaluate the concordance between the two methods.
Fig 1. Tumor sample characteristics andmethod of fixation.
doi:10.1371/journal.pone.0120232.g001
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A sensitivity analysis was carried out by not taking into account samples giving “invalid re-
sults” for at least one of the two methods. Another sensitivity analysis was performed on the
subgroup of samples strictly respecting cobas criteria. A two-sided type one error of 0.05 was
used for all statistical tests. As planned in the protocol, an intermediate analysis was performed
that was not considered in this paper. Due to the descriptive nature of the statistical analysis,
the intermediate analysis did not affect the final analysis. No adjustment of the type one error
was needed.
Results
Melanoma samples
Between December 2012 and April 2013, 420 melanoma samples were consecutively included
in this BRAF V600 mutation parallel testing study conducted in 12 platform laboratories, with
a median number of 32 samples (min 20-max 52) in each laboratory. Most tumor samples
were surgical specimens (79%) and 66% were samples of metastases. Tumor specimens were
provided by the hospital internal pathology laboratory in 57% of the cases and from other labo-
ratories in the remaining cases (Fig. 1).
Pre-analysis of tumor samples
The fixation was performed and controlled by the internal pathology laboratory for 56.4% of
the samples (Fig. 1). The time from sampling to fixation (ischemia) was less than 2 hours
(33.3% of all samples) and duration of fixation was 6–24 hours (25.5% of all samples). The
overwhelming majority of samples were formalin-fixed (92.6%) but three centers also used Al-
cohol-Formol-Acetic acid and two centers also used Excell Plus for fixation.
Most of the samples (90.7%) were subjected to paraffin removal prior to DNA extraction.
No necrosis was detected in 74.2% of the samples. The median percentage of tumor cells was
75% and there were 50% of tumor cells in 91.9% of the samples. Melanin was absent from
51.7% of the samples and was present in moderate to high amounts in 15.9% (Table 1).
DNA extraction was performed manually for 55.2% of the samples using silica-membrane-
based nucleic acid purification kits (Table 1). The remaining extractions (n = 188) were per-
formed using automated methods. The instruments used were Qiacube (Qiagen) for 79 sam-
ples (42.0%), iPrep (Invitrogen) for 50 (26.6%), Maxwell 16 (Promega) for 30 (16.0%), and
Qiasymphony (Qiagen) for 29 (15.4%). Overall, for the HBM, the amount of DNA obtained
was at least 5000 ng in 57.7% of the samples and the median amount of DNA was 6850 ng. At
least 5000 ng of DNA were obtained in 50.6% of the samples with automated extraction and in
62.5% of the samples with manual extraction. The median amount of DNA was 5175 ng and
8234 ng, for automated and manual extraction methods respectively.
Description of the analytical methods used in routine practice
The most frequently used HBM BRAF tests, each used in three centers, were real-time allele-
specific PCR (36.7% of all samples), High Resolution Melting analysis combined with Sanger
sequencing (28.1%) and pyrosequencing (16.0%) (Table 2). Overall, the median size of ampli-
cons was 120 bp [70–232 bp] (Table 2).
A punch was used in four HBM centers (27.9% of all samples) and was used for 10.7% of
the samples with the cobas test. For both methods, when there was no punch, one to three sec-
tions were used in most cases, with a maximum of 10 sections.
The median amount of DNA obtained with the cobas extraction kit was 3635 ng (min 7 ng—
max 58000 ng).
Concordance between BRAF V600 Detection Techniques
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Concordance between cobas and HBM
The frequency of BRAF V600 mutations detected were 34.0% with the cobas vs 35.7% with the
HBMmethods (Table 3). Wild-type genotypes were observed in 63.3% and 62.9% of the sam-
ples using cobas and HBM tests respectively. Overall, the genotyping tests delivered a valid re-
sult (either presence or absence of BRAF mutation) in 97.3% of tumors with the cobas and
98.6% of tumors with HBM tests respectively.
A high concordance rate of 93.3% (392 samples) and a kappa coefficient of 0.86 (95% CI
[0.81; 0.91]) were obtained on comparing cobas and HBMmethods for BRAF V600 mutation
detection in routine practice (Table 3—all samples). The concordance and kappa coefficient
were even better when taking into account the 389 evaluables samples (concordance
Table 1. Pre-analytical sample characteristics overall and according to BRAF mutation.
OVERALLN = 420 BRAF V600
mutationN = 136
No BRAF V600
mutationN = 253
Discordant
resultN = 28
Invalid
resultsN = 3
Slice thickness, N 386 126 230 27 3
Median (min-max) 5 (2–20) 5 (3–20) 5 (2–20) 4 (3–10) 5 (4–20)
<5μm 121 (31.3%) 36 (28.6%) 69 (30.0%) 15 (55.6%) 1 (33.3%)
5μm 265 (68.7%) 90 (71.4%) 161 (70.0%) 12 (44.4%) 2 (66.7%)
Percentage of tumor cells
Median (min-max) 75 (5–100) 70 (15–100) 80 (5–100) 80 (20–100) 90 (80–90)
<50% 34 (8.1%) 13 (9.6%) 17 (6.7%) 4 (14.3%) 0
50% 386 (91.9%) 123 (90.4%) 236 (93.3%) 24 (85.7%) 3 (100%)
DNA extraction method
Automated 188 (44.8%) 57 (41.9%) 110 (43.5%) 19 (67.9%) 2 (66.7%)
Manual 232 (55.2%) 79 (58.1%) 143 (56.5%) 9 (32.1%) 1 (33.3%)
Percentage of necrosis, N 341 113 210 16 2
Median (min-max) 0 (0–60) 0 (0–50) 0 (0–60) 0 (0–20) 0 (0–0)
0% 253 (74.2%) 77 (68.1%) 164 (78.1%) 10 (62.5%) 2 (100.0%)
0% 88 (25.8%) 36 (31.9%) 46 (21.9%) 6 (37.5%) 0
Presence of melanin, N 391 7 12 9 1
Absent 202 (51.7%) 68 (52.7%) 122 (50.6%) 11 (57.9%) 1 (50.0%)
Low 127 (32.5%) 41 (31.8%) 80 (33.2%) 6 (31.6%) 0
Medium 43 (11.0%) 15 (11.6%) 26 (10.8%) 1 (5.3%) 1 (50.0%)
High 19 (4.9%) 5 (3.9%) 13 (5.4%) 1 (5.3%) 0
DNA elution volume (μL)
Median (min-max) 100 (25–185) 100 (25–185) 100 (25–185) 100 (25–185) 60 (50–100)
DNA concentration
(ng/μL), N
392 130 233 26 3
Median (min-max) 76.5 89.0 75.0 32.3 4.0
(0.6–1514) (0.6–1514) (0.6–1465) (1.3–468) (1.5–54)
<5 ng/μL 36 (9.2%) 10 (7.7%) 18 (7.7%) 6 (23.1%) 2 (66.7%)
5 ng/μL 356 (90.8%) 120 (92.3%) 215 (92.3%) 20 (76.9%) 1 (33.3%)
Amount of DNA for HBM
(ng) N
392 130 233 26 3
Median (min-max) 6850 7800 6375 3235 240
(15–102200) (15–102200) (15–75500) (33–37206) (146–2700)
<5000ng 166 (42.3%) 50 (38.5%) 99 (42.5%) 14 (53.8%) 3 (100%)
5000ng 226 (57.7%) 80 (61.5%) 134 (57.5%) 12 (46.2%) 0
doi:10.1371/journal.pone.0120232.t001
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rate = 95.8%, kappa = 0.91 and when taking into account the 185 samples strictly respecting
the cobas criteria (concordance rate = 95,7%, kappa = 0.91).
With HBM, the main types of mutation detected were V600E in 88.7% of the mutations and
V600K in 9.3%, others included V600R (1.3%) and V600D (0.7%). Six samples (1.4%) gave in-
valid results with the in-house method and 11 (2.6%) with the cobas test.
A further analysis performed taking into account the 185 samples strictly respecting the
cobas criteria gave a higher concordance rate of 95.7% and a kappa coefficient of 0.91 (95% CI
[0.85; 0.97]) (Table 3—samples strictly respecting cobas criteria).
Analysis of the discordant cases
Results from the cobas method and the HBM were discordant for 28/420 samples (6.7%)
(Table 3—all samples). Among these 28 discordant cases, 11 had invalid results (8 samples
with the cobas and 3 with HBM) and 17 were true discordant cases (7 with BRAF V600 muta-
tion detected by the cobas only and 10 detected by HBM only). For the 10 samples with BRAF
V600 mutation detected by the HBM but not by the cobas Mutation Test. Five of them were
V600K, D or R mutations. Of these 5 cases, all specimens contained50% of tumor cells, ex-
cept one (40% of tumor cells). Of the other 5 samples with V600E mutation not detected by the
cobas Mutation Test, two of the specimens contained only 20% tumor cells. For the 7 other
samples with BRAF V600 mutation detected by the cobas, but not by HBMs, this result was
confirmed after retesting in 4 samples, the other samples were considered as having invalid re-
sults (n = 2) or not mutated (n = 1).
Univariate logistic regression analyses performed on tumor samples for which there was dis-
cordance between the two methods showed that explanatory factors for discordance may be
Sanger sequencing (p<0.0001), slice thickness (>5μm p = 0.0068) and automated DNA extrac-
tion (p = 0.014) (Table 4). Multivariate analysis showed that automated DNA extraction meth-
od (p = 0.0411) and Sanger sequencing method (p<0.0001) could be two potential explanatory
factors of discordance (Table 4).
Table 2. Analytical method sample characteristics overall and according to BRAF mutation.
OVERALLN = 420 BRAF V600
mutationN = 136
No BRAF V600
mutationN = 253
Discordant
resultN = 28
IndeterminateN = 3
HOME BREW ANALYTICAL METHOD
Method of mutation
detection
Allele-speciﬁc/real time PCR 154 (36.7%) 47 (34.5%) 100 (39.5%) 7 (25.0%) 0
HRM + Sanger sequencing 118 (28.1%) 36 (26.5%) 73 (28.9%) 8 (28.6%) 1 (33.3%)
Pyrosequencing 67 (16.0%) 28 (20.6%) 37 (14.6%) 1 (3.6%) 1 (33.3%)
SNaPshot 30 (7.1%) 11 (8.1%) 19 (7.5%) 0 0
Sanger sequencing 51 (12.1%) 14 (10.3%) 24 (9.5%) 12 (42.9%) 1 (33.3%)
Size of amplicons used
(base pairs [bp])
Median (min-max) 120 (70–232) 120 (70–232) 120 (70–232) 157 (70–232) 107 (82–221)
COBAS ANALYTICAL METHOD
Amount of DNA (ng) N 420 136 253 28 3
Median (min-max) 3635 4680 3350 4085 467
(7–58000) (7–30000) (300–58000) (300–49000) (450–782)
<5000ng 250 (59.5%) 69 (50.7%) 162 (64.0%) 16 (57.1%) 3 (100%)
5000ng 170 (40.5%) 67 (49.3%) 91 (36.0%) 12 (42.9%) 0
doi:10.1371/journal.pone.0120232.t002
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Among the 12 centers participating in this study, the discordance rate ranged from 0% to
31%. The highest discordance rates (13.6% and 31.0%) occurred in two centers using Sanger se-
quencing and long amplicons (157 and 221 bp).
Discussion
The cobas 4800 BRAF V600 Mutation Test has been developed within the strict framework of
clinical trials as a companion diagnostic for targeted cancer therapy with vemurafenib, a BRAF
kinase inhibitor [20].
Here we report on the first prospective and multicenter study assessing in routine practice
testing of BRAF V600 mutations in melanoma samples by HBM in molecular genetics labora-
tories in parallel with the cobas test, an approved and automated assay. Results showed a high
concordance rate of 93.3% (Kappa = 0.86) between the two assessments.
The rates of BRAF V600 mutations observed between the large array of different HBM and
cobas tests were very close (35.7% for HBM and 34.0% for cobas). These results are consistent
with the INCa platforms annual report for the year 2012 during which 3,479 patients under-
went BRAF testing and the frequency of mutation detection for the BRAF gene was 37.6% [28].
In the INCa report, mutation frequency varied depending on the mutation detection method
from 30.6% with TaqMan real-time PCR to 42.7% with allele-specific PCR [28]. Compared to
the general situation in INCa platforms, the present study included less laboratories perform-
ing direct Sanger sequencing and more tests were performed using allele-specific PCR [29]. Al-
lele-specific PCR, High Resolution Melting analysis combined with Sanger sequencing, or
pyrosequencing were used in the centers with the highest annual activity for malignant
melanoma testing.
Table 3. Description of concordances and discordances between the cobas method and home brew methods (all samples N = 420 and samples
strictly respecting cobas criteria N = 185).
All samples Cobas method
Home brew methods BRAF V600 mutation No BRAF V600 mutation Invalid results Total
N = 420
BRAF V600 mutation 136 (32.38%) 10 (2.38%) 4 (0.95%) 150 (35.7%)
No BRAF V600 mutation 7 (1.67%) 253 (60.24%) 4 (0.95%) 264 (62.9%)
Invalid results - 3 (0.71%) 3 (0.71%) 6 (1.4%)
Total 143 (34.0%) 266 (63.3%) 11 (2.6%)
n (%) concordant 392 (93.3%)
n (%) discordant 28 (6.7%) 95% CI: [4.48%; 9.49%]
Kappa coefﬁcient 0.8611 95% CI: [0.8125; 0.9097]
Samples strictly respecting cobas criteria Cobas method
Home brew methods BRAF V600 mutation No BRAF V600 mutation Invalid results Total
N = 185
BRAF V600 mutation 63 (34.05%) 1 (0.54%) 1 (0.54%) 65 (35.1%)
No BRAF V600 mutation 3 (1.62%) 114 (61.62%) 2 (1.08%) 119 (64.3%)
Invalid results - 1 (0.54%) - 1 (0.5%)
Total 66 (35.7%) 116 (62.7%) 3 (1.6%)
n (%) concordant 177 (95.7%)
n (%) discordant 8 (4.3%) 95% CI: [1.89%; 8.34%]
Kappa coefﬁcient 0.9082 95% CI: [0.8472; 0.9692]
doi:10.1371/journal.pone.0120232.t003
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Overall, the rates of invalid results were low, at 1.4% and 2.6% for the HBM and cobas tests
respectively, compared to the 5.1% reported in the INCa report [28]. The INCa report showed
a variation in the frequency of invalid results according to the mutation detection method from
2.5% with allele-specific PCR to 7.0% with direct Sanger sequencing.
Among the 10 cases of discordant BRAF V600E genotypes, it is difficult to conclude whether
this discordance is due to possible contaminations, tumor heterogeneity or to other factors
such as DNA quality or preanalytical parameters. The characteristics of the preanalytical and
analytical methods were mostly similar for samples whatever the BRAF V600 mutation result
(V600 mutation, no V600 mutation, discordant or invalid result). Indeed, any attempts to
highlight specific preanalytical parameters to explain the discordance are hindered as ischemia
and fixation time parameters were missing for about half of the samples. Also, potential
Table 4. Univariate and multivariate analyses of discordant results.
% Discordant§ Univariate analysis p-value Multivariate analysis p-value
OR [95%CI] OR [95%CI]
PRE-ANALYTICAL METHOD
Source of tumor sample
External pathology lab 5.5%
Internal pathology lab 7.6% 1.407 [0.633, 3.126] 0.4017
Slice thickness (μm) (classes)
<5μm 12.4% 2.984 [1.351, 6.589] 0.0068*
5μm 4.5%
Percentage of tumor cells (classes)
<50% 11.8% 2.011 [0.655, 6.177] 0.2223
50% 6.2%
Extraction method
Automated 10.1% 2.786 [1.229, 6.311] 0.0141*
Manual 3.9% 2.487 [1.038;5.964] 0.0411*
HOME BREW METHODS
Amount of DNA (ng)-pre-analytical
<5000ng 8.4% 1.643 [0.739, 3.650] 0.2232
5000ng 5.3%
Sanger sequencing
No 4.3% 6.264 [2.708;14.487] <0.0001*
Yes 23.5% 6.788 [2.995, 15.387] <0.0001*
Punch
No 6.9% 1.170 [0.484, 2.831] 0.7273
Yes 6.0%
COBAS METHOD
Amount of DNA (ng)-pre-analytical
<5000ng 6.4%
5000ng 7.1% 1.111 [0.512, 2.412] 0.7906
Punch
No 6.9% 1.602 [0.367, 6.985] 0.5307
Yes 4.4%
§Percentages are calculated on the total number of samples (N = 420);
*The most highly signiﬁcant values.
doi:10.1371/journal.pone.0120232.t004
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contaminations during automated DNA extraction, although unlikely, cannot be excluded.
Intra-tumoral heterogeneity should also be taken into account. Indeed, using laser microdissec-
tion followed by mutation specific Snapshot assay, a substantial proportion of individual
tumor specimens were found to contain a mixture of BRAF mutant and wild-type melanoma
cells [30]. In addition, a low percentage of tumor cells may possibly explain one case of discor-
dance according to the molecular technique sensitivity threshold.
As expected, based on preclinical and clinical studies involving retrospective sequencing,
rare V600R, V600D and V600K mutations were detected with low sensitivity by cobas
[22,31,32]. In a study of 295 melanoma samples comparing the cobas 4800 BRAF V600 Muta-
tion Test with direct Sanger sequencing assays, the cobas test was less sensitive for mutations
other than the single-nucleotide V600E mutation [33]. In this retrospective analysis of BRAF
V600 mutations, twenty samples were excluded because of invalid results (by cobas (n = 3), se-
quencing (n = 15), or both (n = 2)) and 23 samples with positive sequencing results gave nega-
tive cobas results [33].
Tumors with other V600 mutations, such as V600K, are sensitive to vemurafenib treatment
[34]. In our study, only 2 discordant samples had V600K mutations, as detected by HBM but
not with cobas.
Concerning the analytical genotyping method used, a higher discordance rate was ob-
served in centers using direct Sanger sequencing with long amplicons for mutation detection.
Low sensitivity (15–30%) of the Sanger sequencing method has previously been reported
[22,23,35,36]. Furthermore, false positive detections by the Sanger method could be due to
contamination or background noise [35]. Conversely, high concordance was observed be-
tween the cobas method and the High Resolution Melting analysis technique followed by
Sanger sequencing.
Interestingly, both pyrosequencing and High Resolution Melting analysis methods have
been shown by two French groups participating in this study to provide concordant data with
immunohistochemical detection of the BRAF p.V600E protein when applying robust and sim-
ple interpretation criteria [9,27]. Although rare false negative cases exist using immunohis-
tochemistry as a screening tool, these cases would be tested with DNA-based methods in a
hierarchical algorithm [37]. On the other hand, "false positive" cases detected by immunohis-
tochemistry were reported wild type using direct sequencing, but further detected as mutated
using Pyrosequencing [37]. Altogether our molecular comparison between cobas and HB
methods also indicated that direct sequencing should not be used in routine testing of melano-
ma samples as well as in technical comparison since this generates a high rate of discordant
cases.
In conclusion, the results of this first prospective study comparing the cobas 4800 BRAF
V600 Mutation Test and various HBM developed in national platforms in France allows us to
draw 2 main conclusions: standard DNA sequencing (especially using long DNA amplicons)
generates a significant proportion of invalid results, and the cobas 4800 BRAF V600 mutation
assay is efficient for testing V600E BRAF mutations.
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